Review Timeline | CrossMark Policy | ClinMed Features
logo
International Journal of

Clinical Biostatistics and BiometricsISSN: 2469-5831

Archive

 Open Access DOI:10.23937/2469-5831/1510015

Analogs of the Wilcoxon-Mann-Whitney Test When There is a Covariate

Rand R Wilcox

Article Type: Research Article | First Published: December 22, 2017

Certainly the best-known method for making inferences about p is the Wilcoxon-Mann-Whitney (WMW) test. It is well known, however, that under general conditions, the WMW method uses an incorrect estimate of the standard error. Numerous methods have been derived for dealing with this issue....

 Open Access DOI:10.23937/2469-5831/1510014

Bayesian Cox Proportional Hazards Model in Survival Analysis of HACE1 Gene with Age at Onset of Alzheimer's Disease

Ke-Sheng Wang, Ying Liu, Shaoqing Gong, Chun Xu, Xin Xie, Liang Wang and Xingguang Luo

Article Type: Research Article | First Published: December 01, 2017

Alzheimer's Disease (AD), the most common form of dementia, is a chronic neurodegenerative disease. The HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 (HACE1) gene is expressed in human brain and may play a role in the pathogenesis of neurodegenerative disorders....

 Open Access DOI:10.23937/2469-5831/1510013

On Sample Size Calculation for Exact Group Sequential Tests for Rare Disease

Man Jin and James L Kepner

Article Type: Research Article | First Published: October 09, 2017

For a rare disease, all the patients having the disease constitute a small population, and the standard single-stage hypergeometric test is uniformly most powerful to evaluate the response probability of a specific treatment regimen....

 Open Access DOI:10.23937/2469-5831/1510012

A Systematic Approach to Increase Reproducibility in Simulation Studies

Xiaoyong Wu and Shesh N Rai

Article Type: Research Article | First Published: October 07, 2017

Reproducibility of results in simulation studies plays a key role in statistical science. Although P-value occupies a prominent place for determining statistical significance in replicate studies, there is always possibility of extra variability across samples leading to irreproducible results. Recently, Halsey, et al....

 Open Access DOI:10.23937/2469-5831/1510011

Can We Identify Patients at High Risk of Harm under a Generally Safe Intervention?

Gerd K Rosenkranz

Article Type: Research Article | First Published: September 23, 2017

Personalized medicine today is primarily addressing efficacy. Here we investigate and illustrate the role that precision medicine could play in drug safety by supporting the identification of subjects at high risk of harm by an otherwise safe and efficacious treatment. Predicting potential harm requires high sensitivity of a classification rule....

 Open Access DOI:10.23937/2469-5831/1510010

Inference Based on Small Randomized Oncology Clinical Trials: Is the Observed Treatment Effect True?

Joyce Cheng, Hui Zhang, Shenghui Tang and Rajeshwari Sridhara

Article Type: Original Article | First Published: May 20, 2017

The drug development paradigm in oncology has changed in recent times as developments in science and technology have led to more targeted therapies. Drug products are receiving marketing approvals based on single randomized studies enrolling 100-200 patients, including early phase (phase II) clinical trials....

Volume 3
Issue 1